Home
 
Home
Stock Research
Fund Research
Markets
Forex
Options
Retirement
Real Estate
News
Commentary
University
Featured Content
Free Newsletters
Financial Glossary
Business Glossary
The market in:
: :
LCAV Overview
LCAV Charts
LCAV News
LCAV Profile
LCAV Analysis
LCAV Offers

InvestorGuide Stock Analysis

LCAV has yet to be featured as an InvestorGuide.com Stock of the Day. But read about these related stocks from the Healthcare Sector:

Onyx Writes $276M Check to Proteolix
Excerpt from the InvestorGuide.com Stock of the Day on 10/12/2009

The season of mergers and acquisitions is still charging forward. Companies are seeking out great deals and the time to make these purchases has arrived. Onyx Pharmaceuticals Inc. is the latest to join the growing list of companies snapping up other businesses now that the economy is showing signs of a recovery. Onyx has agreed to purchase Proteolix Inc, a privately held biotechnology company for $276 million. What elements of Proteolix made it an attractive purchase for Onyx? Will this deal become lucrative for the pharmaceutical company or will the company need a dose of its own medicine?

Onyx Pharmaceuticals Inc. is not a well-known leader among drug development companies. As with most companies of this sort, Onyx has struggled to remain profitable. Onyx's reliance on its partnership with the German drug giant Bayer and the cancer drug Nexavar have been the primary source of income for the company. This fact has caused investors to look at the company as a risky investment due to its lack of diversity in income sources. Investors have been anxiously waiting to see the next move from the company ever since it raised $300 million in August. There are a few factors that most likely contributed to Onyx's decision to purchase Proteolix. Onyx's cancer therapy Nexavar missed its main goal in a Phase II trial in breast cancer last month. As mentioned earlier, this is one of the primary sources of income for the drug company. Despite the recent failure of Nexavar, Chief Executive Officer Tony Coles expects the drug to bring in $1 billion in revenue next year. Another factor that may have made Proteolix enticing to Onyx is the fact that it is currently testing carfilzomib as a treatment for multiple myeloma, the second most common blood cancer after leukemia. If these tests prove to be successful, this will give Onyx entry into the $16 billion market for hematologic cancer. Entry into this market will not be cheap for Onyx. The company may have to pay an additional $575 million over the course of years for development and regulatory approvals of the experimental drug. This will look like a drop in the bucket if Onyx is able to capture only a small percentage of the multibillion dollar market. More >

Subscribe to the Stock of the Day!
 

Add to tracker

InvestorGuide Stock of the Day RSS feed

RSS
Will Shareholders Agree to Sell Genentech?
Excerpt from the InvestorGuide.com Stock of the Day on 2/2/2009

About six months ago, Swiss drugmaker Roche offered to buy out all of Genentech's remaining stock in a deal worth $44 billion. This equals about $89 per share. This represented a 9 percent premium at the time. The board of directors evaluated this offer and about a month later, rejected the bid saying the price significantly undervalued the company's worth and growth potential. Little else has occurred since, but on Friday, Roche took the deal directly to shareholders asking to buy their equity for $86.50 per share. The US biotech firm advised shareholders not to take action so it can review its current position and prepare a formal response. Investors and analysts expect an announcement within two weeks. By the end of Friday, Genentech's stock closed at $81.50, indicating investors are complying. Having been rejected once by the company, will Roche be rejected a second time by shareholders? More >

Trading Offers

•
Buy stock for just $4

Special Offers

•
Learn to spot opportunities in any market with a Risk-Free* 30-day trial from Investools.

LCA-Vision (LCAV) Upgrades

Date
Analyst
Old Rating
New Rating
05/27/2008
RBC Capital
Underperform
Sector Perform
08/16/2006
Raymond James
Strong Buy
Outperform

LCA-Vision (LCAV) Downgrades

Date
Analyst
Old Rating
New Rating
06/05/2009
Maxim Group
Hold
Sell
06/05/2009
Maxim Group
Hold
Sell
02/15/2008
RBC Capital
Sector Perform
Underperform
06/12/2007
Matrix Research
Buy
Hold
10/02/2006
Raymond James
Underperform
Market Perform
10/02/2006
Raymond James
Market Perform
Strong Buy

LCA-Vision (LCAV) New Coverage

Date
Analyst
Rating
09/28/2007
FTN Midwest
Buy
Buy stock for just $4

Special Offers

Buy stock for just $4
www.sharebuilder.com
Learn to spot opportunities in any market with a Risk-Free* 30-day trial from Investools.
www.investools.com
Download a free Options Fundamentals Podcast, from The Options Industry Council.
OptionsEducation.org

LCAV Links

Guru Analysis:
MSN Money | Morningstar | Stock Consultant

Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet

Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com

Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy LCAV for just $4

Competitor Analysis

TLC Vision
Continucare
Express Scripts
NovaMed
Get Analysis For: